Vishal Bhatnagar
Overview
Explore the profile of Vishal Bhatnagar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sangwan N, Bhatnagar V
Sci Rep
. 2025 Jan;
15(1):2508.
PMID: 39833294
As digital media grows, there is an increasing demand for engaging content that can captivate audiences. Along with that, the monetary conversion of those engaging videos is also increased. This...
2.
Sarraf Yazdy M, Kasamon Y, Gu W, Rodriguez L, Jin S, Bhatnagar V, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5521-5526.
PMID: 39404868
In April 2023, the U.S. FDA granted regular approval to polatuzumab vedotin-piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (pola+R-CHP) for adult patients who have previously untreated...
3.
Horodniceanu E, Datla T, Murugappan M, Kanapuru B, Amiri-Kordestani L, Larkins E, et al.
Value Health
. 2024 Oct;
28(1):108-115.
PMID: 39389354
Objectives: Incorporating patient-reported outcomes (PROs) to assess symptomatic adverse events (AEs) in cancer clinical trials (CTs) is important to characterize treatment tolerability. Cancer therapies approved over the past decade have...
4.
Yap C, Aiyegbusi O, Alger E, Basch E, Bell J, Bhatnagar V, et al.
EClinicalMedicine
. 2024 Oct;
76:102838.
PMID: 39386161
Early phase clinical trials provide an initial evaluation of therapies' risks and benefits to patients, including safety and tolerability, which typically relies on reporting outcomes by investigator and laboratory assessments....
5.
Fallah J, Heiss B, Joeng H, Weinstock C, Gao X, Pierce W, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5003-5008.
PMID: 39248780
On December 14, 2023, the U.S. FDA approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following treatment with a PD-1/PD-L1 inhibitor and a...
6.
Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks T, et al.
J Clin Oncol
. 2024 Aug;
42(34):4103-4113.
PMID: 39159418
Purpose: The US Food and Drug Administration (FDA) approved capivasertib in combination with fulvestrant for adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, or...
7.
Chang E, Hahn N, Lerner S, Fallah J, Agrawal S, Kamat A, et al.
Bladder Cancer
. 2024 Jul;
9(3):271-286.
PMID: 38993184
Background: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical...
8.
Coles T, Plyler K, Hernandez A, Fillipo R, Henke D, Arizmendi C, et al.
Qual Life Res
. 2024 Apr;
33(7):1829-1839.
PMID: 38642219
Purpose: Successful patient-focused drug development involves selecting and measuring outcomes in clinical trials that are important to patients. The U.S. Food & Drug Administration's definition of clinical benefit includes how...
9.
Coles T, Fillipo R, Plyler K, Hernandez A, Henke D, Arizmendi C, et al.
Qual Life Res
. 2024 Apr;
33(7):1819-1828.
PMID: 38642217
Purpose: The U.S. Food & Drug Administration has identified physical functioning (PF) as a core patient-reported outcome (PRO) in cancer clinical trials. The purpose of this study was to identify...
10.
Aiyegbusi O, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, et al.
Nat Med
. 2024 Feb;
30(3):650-659.
PMID: 38424214
Patient-reported outcomes (PROs) are increasingly used in healthcare research to provide evidence of the benefits and risks of interventions from the patient perspective and to inform regulatory decisions and health...